BioVector? CHLA-90 人神經(jīng)母細(xì)胞瘤細(xì)胞系 / BioVector? CHLA-90 Human Neuroblastoma Cell Line

通用定義 / General Definition:

BioVector? CHLA-90 是一種源自人類神經(jīng)母細(xì)胞瘤 (Neuroblastoma) 的細(xì)胞系。該細(xì)胞系建立于一名接受過誘導(dǎo)化療、手術(shù)及自體骨髓移植后復(fù)發(fā)的患兒。CHLA-90 在分子生物學(xué)上非常具有代表性，它具有 MYCN 基因擴(kuò)增 且攜帶 TP53 基因突變。在神經(jīng)母細(xì)胞瘤研究中，這種“雙重打擊”（MYCN 擴(kuò)增 + TP53 功能缺失）通常與極高的耐藥性和極差的預(yù)后相關(guān)。因此，該細(xì)胞系是研究晚期復(fù)發(fā)性腫瘤耐藥機(jī)制、細(xì)胞凋亡逃逸以及篩選新一代抗腫瘤藥物的關(guān)鍵工具。

BioVector? CHLA-90 is a human cell line derived from Neuroblastoma. It was established from a patient who relapsed following intensive induction chemotherapy, surgery, and autologous bone marrow transplantation. CHLA-90 is molecularly significant as it features MYCN gene amplification combined with a TP53 gene mutation. In neuroblastoma research, this "double hit" (MYCN amplification + loss of TP53 function) is associated with high-level drug resistance and poor clinical outcomes. Consequently, this line is a pivotal tool for studying resistance mechanisms in advanced relapsed tumors, evasion of apoptosis, and screening next-generation anti-cancer therapeutics.

BioVector? CHLA-90 技術(shù)說明書 (Technical Datasheet)

中文版說明書 (Chinese Datasheet)

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? CHLA-90 人神經(jīng)母細(xì)胞瘤細(xì)胞

• 組織來源： 轉(zhuǎn)移灶/復(fù)發(fā)腫瘤組織

• 分子特征：MYCN 擴(kuò)增；TP53 突變；通常表現(xiàn)為對 p53 依賴性凋亡誘導(dǎo)藥物（如某些傳統(tǒng)化療藥）的強(qiáng)烈耐受。

• 生長特性： 貼壁生長。

• 細(xì)胞形態(tài)： 呈現(xiàn)典型的小圓細(xì)胞形態(tài)，胞漿極少，有時可見短小的神經(jīng)突起。

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? IMDM 或 DMEM/F-12 (1:1)。

• 血清添加： 10% - 20% BioVector? 優(yōu)質(zhì)胎牛血清 (FBS)。

• 補充因子： 建議添加 1x ITS (胰島素-轉(zhuǎn)移蛋白-硒) 和 L-谷氨酰胺，以增強(qiáng)復(fù)發(fā)細(xì)胞系的穩(wěn)健性。

• 培養(yǎng)環(huán)境： 37 攝氏度，5% $CO_2$。

• 傳代比例： 1:2 至 1:4；該細(xì)胞生長速度適中。

3. 細(xì)胞應(yīng)用

• 凋亡逃逸研究： 探索 TP53 突變?nèi)绾斡绊懩[瘤細(xì)胞對 DNA 損傷反應(yīng)的調(diào)節(jié)。

• 耐藥篩選： 評估新型小分子抑制劑（如 ALK 抑制劑、PARP 抑制劑或免疫代謝藥物）在極端耐藥背景下的效能。

• 轉(zhuǎn)錄組分析： 研究 MYCN 與突變型 p53 在促進(jìn)腫瘤演進(jìn)中的協(xié)同作用。

4. 注意事項

• 血清質(zhì)量敏感性： 鑒于該細(xì)胞系源自多次治療后的樣本，其對血清質(zhì)量較為敏感，建議使用經(jīng)過驗證的同批次優(yōu)質(zhì)胎牛血清。

• 生長形態(tài)監(jiān)控： 細(xì)胞在低匯合度下可能生長較慢，建議在接種時保持較高的起始密度（約 $5 \times 10^4$ cells/$cm^2$）。

English Datasheet

1. General Product Information

• Product Name: BioVector? CHLA-90 Human Neuroblastoma Cell Line

• Source: Metastatic site/Relapsed tumor tissue

• Molecular Profile:MYCN Amplified; TP53 Mutated; typically exhibits profound resistance to drugs that rely on p53-mediated apoptosis.

• Growth Properties: Adherent.

• Morphology: Small round cells with minimal cytoplasm; may display occasional short neurite-like processes.

2. Culture Conditions

• Basal Medium: BioVector? IMDM or DMEM/F-12 (1:1).

• Serum Supplement: 10% - 20% BioVector? Fetal Bovine Serum (FBS).

• Supplements: Supplementation with 1x ITS (Insulin-Transferrin-Selenium) and L-Glutamine is recommended to support the robustness of this relapsed-derived line.

• Incubation: 37°C, 5% $CO_2$.

• Subculturing: 1:2 to 1:4 ratio; growth rates are moderate.

3. Applications

• Apoptosis Evasion Studies: Investigating how TP53 mutations alter the cellular response to DNA-damaging agents.

• Drug Discovery: Evaluating the efficacy of novel small molecules (e.g., ALK, PARP, or Aurora Kinase inhibitors) within a highly resistant genetic background.

• Functional Genomics: Studying the cooperativity between MYCN overexpression and p53 dysfunction in driving neuroblastoma progression.

4. Key Usage Notes

• Serum Sensitivity: As a late-stage relapse line, CHLA-90 is sensitive to serum variability; BioVector? recommends using high-quality, heat-inactivated FBS from a consistent lot.

• Seeding Density: Cells may exhibit a lag phase if seeded too sparsely. Maintaining an optimal seeding density (approx. $5 \times 10^4$ cells/$cm^2$) is crucial for consistent culture expansion.

注意 / Note: BioVector? CHLA-90 應(yīng)在生物安全二級 (BSL-2) 條件下操作。由于攜帶 TP53 突變，該細(xì)胞系在基因組穩(wěn)定性方面可能較差，建議在實驗關(guān)鍵節(jié)點進(jìn)行 STR 鑒定及核型分析。

BioVector? CHLA-90 should be handled under Biosafety Level 2 (BSL-2) conditions. Due to the TP53 mutation, the line may possess inherent genomic instability; BioVector? recommends routine STR profiling and karyotypic analysis during long-term culture.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址

http://www.nedfriskphoto.com